|
Neonatal Intensive Care Drug Manual
|
| bet | 526/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Ranitidine
Revision Date : 2-3-2020
|
Approved: TC, KOH
|
Alert
|
Note: This medications licence is currently suspended from the Australian Register of Therapeutic Goods and is unavailable for use in Australia.
Exposure to H2 receptor antagonists may be associated with increased risk of NEC, infections and mortality in preterm infants and its use needs to balance safety against risks.
|
Indication
|
Treatment of gastroesophageal reflux disease (GORD)
Post-operative prophylaxis in congenital tracheoesophageal fistula and oesophageal atresia
Prophylaxis to reduce stress gastric ulcers/gastrointestinal haemorrhage
Treatment of bradycardias attributed to GOR (not recommended)
|
Action
|
Ranitidine is a histamine2 receptor antagonist. Ranitidine decreases acid secretion by inhibiting histamine2 receptors on gastric parietal cells.
|
Drug Type
|
Histamine2 receptor antagonist
|
Trade Name
|
APO-Ranitidine Tablets [Apotex]; Ausran Tablets [Aspen]; Chemists' Own Ranitidine Forte Tablets [Chemists' Own]; GenRx Ranitidine Tablets [Apotex]; Ranitidine Sandoz Tablets [Sandoz], Zantac Dispersible tablets [Aspen]; Zantac Effervescent tablets [Aspen]; Zantac Syrup [Aspen]; Zantac Tablets [Aspen]
Ranitidine Sandoz Injection 50 mg/5 mL [Sandoz]; Zantac Concentrate for injection [Aspen]
|
Presentation
|
150 mg tablet
150 mg/10 mL liquid (contains ~7.5% w/v ethanol), 300 mL
Zantac: 25 mg/mL, 2 mL injection (50 mg in 2 mL)
Ranitidine Sandoz: 10 mg/mL, 5 mL injection (50 mg in 5 mL)
|
|
|
| |
